...
首页> 外文期刊>Allergy, Asthma & Clinical Immunology >New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy
【24h】

New efficacy of LTRAs (montelukast sodium): it possibly prevents food-induced abdominal symptoms during oral immunotherapy

机译:LTRAs(孟鲁司特钠)的新功效:它可以预防口服免疫治疗期间食物引起的腹部症状

获取原文
           

摘要

Background The aim of the study was to elucidate whether leukotriene receptor antagonists (LTRAs) can prevent severe allergic reactions, which occur during oral immunotherapy (OIT) in children with food allergies. Findings Five children with food allergies [3 allergic to hen’s egg (HE), 1 to wheat, and one to cow’s milk (CM); aged between 7 and 12 years; median, 8.5?years] who were started on LTRAs during OIT were retrospectively selected from among 63 children undergoing OIT. In the rush phase, after the administration of the initial dose which was set in open food challenge test, the subsequent doses were increased by approximately 1.2 times of the previous dose and were administered every 2 hours, 4 times a day. The target doses of hen’s egg, wheat (udon noodle), and cow’s milk in the rush phase were 50?g, 200?g, and 200?ml, respectively. The ingestion of the target dose was continued at home every day for at least a year in the maintained phase. Four participants experienced intractable abdominal pain during the rush phase; therefore, the loading dose was not increased in these children. However, the administration of LTRAs prevented their symptoms, resulting in the completion of the rush phase. One participant also experienced intractable abdominal pain during the maintenance phase. After receiving LTRAs, the target dose was able to tolerated. Conclusion The findings from this retrospective study suggest that the administration of LTRAs is useful for the prevention of adverse allergic reactions such as abdominal pain during OIT.
机译:背景研究的目的是阐明白三烯受体拮抗剂(LTRAs)是否可以预防严重的过敏反应,这种过敏反应发生在对食物过敏的儿童进行口服免疫治疗(OIT)期间。发现5名儿童对食物过敏[3名对鸡蛋过敏(HE),1名对小麦过敏,1名对牛奶(CM)过敏;年龄在7至12岁之间;从63例接受OIT的儿童中回顾性地选择了在OIT期间开始LTRA的中位数[8.5岁]。在仓促阶段,在开始在开放食物激发试验中设定的初始剂量给药后,随后的剂量增加到先前剂量的约1.2倍,并且每2小时一次,每天4次。在高峰期,鸡蛋,小麦(乌冬面)和牛奶的目标剂量分别为50微克,200微克和200微毫升。在维持阶段,每天至少在家中摄入目标剂量至少一年。四名参与者在匆忙阶段经历了顽固的腹痛;因此,这些儿童的负荷剂量并未增加。但是,LTRAs的使用可以预防其症状,从而导致匆忙阶段的完成。一名参与者在维持阶段还经历了顽固性腹痛。接受LTRAs后,可以耐受目标剂量。结论这项回顾性研究的结果表明,LTRAs的给药可用于预防OIT期间的不良变态反应,如腹痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号